ID   M3K11_HUMAN             Reviewed;         847 AA.
AC   Q16584; B4DS76; Q53H00; Q59F06; Q6P2G4;
DT   19-JUL-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   12-OCT-2022, entry version 201.
DE   RecName: Full=Mitogen-activated protein kinase kinase kinase 11;
DE            EC=2.7.11.25;
DE   AltName: Full=Mixed lineage kinase 3;
DE   AltName: Full=Src-homology 3 domain-containing proline-rich kinase;
GN   Name=MAP3K11 {ECO:0000312|HGNC:HGNC:6850};
GN   Synonyms=MLK3 {ECO:0000303|PubMed:15258589}, PTK1, SPRK
GN   {ECO:0000312|EMBL:AAA19647.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1] {ECO:0000305, ECO:0000312|EMBL:AAA19647.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY,
RP   TISSUE SPECIFICITY, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF LYS-144 AND
RP   GLU-164.
RC   TISSUE=Megakaryocyte;
RX   PubMed=8195146; DOI=10.1016/s0021-9258(17)36578-x;
RA   Gallo K.A., Mark M.R., Scadden D.T., Wang Z., Gu Q., Godowski P.J.;
RT   "Identification and characterization of SPRK, a novel src-homology 3
RT   domain-containing proline-rich kinase with serine/threonine kinase
RT   activity.";
RL   J. Biol. Chem. 269:15092-15100(1994).
RN   [2] {ECO:0000305, ECO:0000312|EMBL:AAA59859.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=Thymus {ECO:0000312|EMBL:AAA59859.1};
RX   PubMed=8183572;
RA   Ing Y.L., Leung I.W.L., Heng H.H.Q., Tsui L.-C., Lassam N.J.;
RT   "MLK-3: identification of a widely-expressed protein kinase bearing an SH3
RT   domain and a leucine zipper-basic region domain.";
RL   Oncogene 9:1745-1750(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Liver, and Spleen;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [6] {ECO:0000305, ECO:0000312|EMBL:AAH64543.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT HIS-252.
RC   TISSUE=Brain {ECO:0000312|EMBL:AAH11263.1}, and Hippocampus
RC   {ECO:0000269|PubMed:15489334};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   INTERACTION WITH MAP2K4/MKK4, AND FUNCTION IN PHOSPHORYLATION OF
RP   MAP2K4/MKK4.
RX   PubMed=9003778; DOI=10.1002/j.1460-2075.1996.tb01094.x;
RA   Tibbles L.A., Ing Y.L., Kiefer F., Chan J., Iscove N., Woodgett J.R.,
RA   Lassam N.J.;
RT   "MLK-3 activates the SAPK/JNK and p38/RK pathways via SEK1 and MKK3/6.";
RL   EMBO J. 15:7026-7035(1996).
RN   [8] {ECO:0000305}
RP   ACTIVITY REGULATION, AND HOMODIMERIZATION.
RX   PubMed=9829970; DOI=10.1074/jbc.273.49.32408;
RA   Leung I.W.L., Lassam N.J.;
RT   "Dimerization via tandem leucine zippers is essential for the activation of
RT   the mitogen-activated protein kinase kinase kinase, MLK-3.";
RL   J. Biol. Chem. 273:32408-32415(1998).
RN   [9] {ECO:0000305}
RP   ACTIVITY REGULATION, PHOSPHORYLATION AT THR-277 AND SER-281, AND
RP   MUTAGENESIS OF LYS-144; THR-277; THR-278 AND SER-281.
RX   PubMed=11053428; DOI=10.1074/jbc.m004092200;
RA   Leung I.W.L., Lassam N.J.;
RT   "The kinase activation loop is the key to mixed lineage kinase-3 activation
RT   via both autophosphorylation and hematopoietic progenitor kinase 1
RT   phosphorylation.";
RL   J. Biol. Chem. 276:1961-1967(2001).
RN   [10] {ECO:0000305}
RP   PHOSPHORYLATION AT SER-524; SER-555; SER-556; SER-654; SER-705; SER-724;
RP   SER-727; SER-740; SER-758; SER-770 AND SER-793.
RX   PubMed=11969422; DOI=10.1021/bi016075c;
RA   Vacratsis P.O., Phinney B.S., Gage D.A., Gallo K.A.;
RT   "Identification of in vivo phosphorylation sites of MLK3 by mass
RT   spectrometry and phosphopeptide mapping.";
RL   Biochemistry 41:5613-5624(2002).
RN   [11] {ECO:0000305}
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=12529434; DOI=10.1091/mbc.e02-02-0115;
RA   Swenson K.I., Winkler K.E., Means A.R.;
RT   "A new identity for MLK3 as an NIMA-related, cell cycle-regulated kinase
RT   that is localized near centrosomes and influences microtubule
RT   organization.";
RL   Mol. Biol. Cell 14:156-172(2003).
RN   [12] {ECO:0000305}
RP   FUNCTION.
RX   PubMed=15258589; DOI=10.1038/ncb1152;
RA   Chadee D.N., Kyriakis J.M.;
RT   "MLK3 is required for mitogen activation of B-Raf, ERK and cell
RT   proliferation.";
RL   Nat. Cell Biol. 6:770-776(2004).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-507, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-11; SER-507; SER-548;
RP   SER-705; THR-708; SER-748; SER-758; SER-793 AND SER-815, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-789 AND SER-793, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-394; SER-507; SER-548;
RP   SER-693; SER-705; SER-748; SER-758; SER-789 AND SER-793, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-789 AND SER-793, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-507; SER-524 AND SER-548, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [20]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-151 AND GLY-282.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Activates the JUN N-terminal pathway. Required for serum-
CC       stimulated cell proliferation and for mitogen and cytokine activation
CC       of MAPK14 (p38), MAPK3 (ERK) and MAPK8 (JNK1) through phosphorylation
CC       and activation of MAP2K4/MKK4 and MAP2K7/MKK7. Plays a role in mitogen-
CC       stimulated phosphorylation and activation of BRAF, but does not
CC       phosphorylate BRAF directly. Influences microtubule organization during
CC       the cell cycle. {ECO:0000269|PubMed:12529434,
CC       ECO:0000269|PubMed:15258589, ECO:0000269|PubMed:8195146,
CC       ECO:0000269|PubMed:9003778}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.25;
CC         Evidence={ECO:0000269|PubMed:8195146};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.25; Evidence={ECO:0000269|PubMed:8195146};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000250|UniProtKB:P80192};
CC   -!- ACTIVITY REGULATION: Homodimerization via the leucine zipper domains is
CC       required for autophosphorylation and subsequent activation.
CC       {ECO:0000269|PubMed:11053428, ECO:0000269|PubMed:9829970}.
CC   -!- SUBUNIT: Homodimer; undergoes dimerization during activation
CC       (PubMed:9829970). Interacts with MAP2K4/MKK4 (By similarity). Interacts
CC       with MAP2K7/MKK7 (PubMed:9003778). Found in a complex with SH3RF1,
CC       RAC1, MAP2K7/MKK7, MAPK8IP1/JIP1 and MAPK8/JNK1 (By similarity).
CC       {ECO:0000250|UniProtKB:Q80XI6, ECO:0000269|PubMed:9003778,
CC       ECO:0000269|PubMed:9829970}.
CC   -!- INTERACTION:
CC       Q16584; P60953: CDC42; NbExp=3; IntAct=EBI-49961, EBI-81752;
CC       Q16584; P35240: NF2; NbExp=4; IntAct=EBI-49961, EBI-1014472;
CC       Q16584; P70218: Map4k1; Xeno; NbExp=3; IntAct=EBI-49961, EBI-2906801;
CC       Q16584; PRO_0000045602 [Q99IB8]; Xeno; NbExp=5; IntAct=EBI-49961, EBI-6927873;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubule organizing
CC       center, centrosome {ECO:0000269|PubMed:12529434}. Note=Location is cell
CC       cycle dependent.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q16584-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q16584-2; Sequence=VSP_056183;
CC   -!- TISSUE SPECIFICITY: Expressed in a wide variety of normal and
CC       neoplastic tissues including fetal lung, liver, heart and kidney, and
CC       adult lung, liver, heart, kidney, placenta, skeletal muscle, pancreas
CC       and brain. {ECO:0000269|PubMed:8183572, ECO:0000269|PubMed:8195146}.
CC   -!- PTM: Autophosphorylation on serine and threonine residues within the
CC       activation loop plays a role in enzyme activation. Thr-277 is likely to
CC       be the main autophosphorylation site. Phosphorylation of Ser-555 and
CC       Ser-556 is induced by CDC42. {ECO:0000269|PubMed:11053428,
CC       ECO:0000269|PubMed:11969422, ECO:0000269|PubMed:8195146}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. MAP kinase kinase kinase subfamily.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAD92892.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U07747; AAA19647.1; -; mRNA.
DR   EMBL; L32976; AAA59859.1; -; mRNA.
DR   EMBL; AB209655; BAD92892.1; ALT_INIT; mRNA.
DR   EMBL; AK299609; BAG61538.1; -; mRNA.
DR   EMBL; AK316032; BAH14403.1; -; mRNA.
DR   EMBL; AK222781; BAD96501.1; -; mRNA.
DR   EMBL; AP001362; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC011263; AAH11263.1; -; mRNA.
DR   EMBL; BC064543; AAH64543.1; -; mRNA.
DR   CCDS; CCDS8107.1; -. [Q16584-1]
DR   PIR; A53800; A53800.
DR   RefSeq; NP_002410.1; NM_002419.3. [Q16584-1]
DR   PDB; 5K26; X-ray; 1.20 A; A/B=41-105.
DR   PDB; 5K28; X-ray; 1.50 A; A/B=44-105.
DR   PDB; 6AQB; X-ray; 1.50 A; A/B=41-108.
DR   PDB; 6CQ7; X-ray; 2.00 A; A=41-108.
DR   PDBsum; 5K26; -.
DR   PDBsum; 5K28; -.
DR   PDBsum; 6AQB; -.
DR   PDBsum; 6CQ7; -.
DR   AlphaFoldDB; Q16584; -.
DR   SMR; Q16584; -.
DR   BioGRID; 110442; 50.
DR   CORUM; Q16584; -.
DR   IntAct; Q16584; 19.
DR   MINT; Q16584; -.
DR   STRING; 9606.ENSP00000309597; -.
DR   BindingDB; Q16584; -.
DR   ChEMBL; CHEMBL2708; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q16584; -.
DR   GuidetoPHARMACOLOGY; 2071; -.
DR   iPTMnet; Q16584; -.
DR   PhosphoSitePlus; Q16584; -.
DR   BioMuta; MAP3K11; -.
DR   DMDM; 71153819; -.
DR   CPTAC; CPTAC-1047; -.
DR   CPTAC; CPTAC-833; -.
DR   CPTAC; CPTAC-835; -.
DR   CPTAC; CPTAC-836; -.
DR   CPTAC; CPTAC-837; -.
DR   CPTAC; CPTAC-838; -.
DR   CPTAC; CPTAC-839; -.
DR   CPTAC; CPTAC-840; -.
DR   EPD; Q16584; -.
DR   jPOST; Q16584; -.
DR   MassIVE; Q16584; -.
DR   MaxQB; Q16584; -.
DR   PaxDb; Q16584; -.
DR   PeptideAtlas; Q16584; -.
DR   PRIDE; Q16584; -.
DR   ProteomicsDB; 5004; -.
DR   ProteomicsDB; 60929; -. [Q16584-1]
DR   ABCD; Q16584; 1 sequenced antibody.
DR   Antibodypedia; 29871; 316 antibodies from 33 providers.
DR   DNASU; 4296; -.
DR   Ensembl; ENST00000309100.8; ENSP00000309597.3; ENSG00000173327.8. [Q16584-1]
DR   Ensembl; ENST00000530153.5; ENSP00000433886.1; ENSG00000173327.8. [Q16584-2]
DR   GeneID; 4296; -.
DR   KEGG; hsa:4296; -.
DR   MANE-Select; ENST00000309100.8; ENSP00000309597.3; NM_002419.4; NP_002410.1.
DR   UCSC; uc001oew.4; human. [Q16584-1]
DR   CTD; 4296; -.
DR   DisGeNET; 4296; -.
DR   GeneCards; MAP3K11; -.
DR   HGNC; HGNC:6850; MAP3K11.
DR   HPA; ENSG00000173327; Low tissue specificity.
DR   MIM; 600050; gene.
DR   neXtProt; NX_Q16584; -.
DR   OpenTargets; ENSG00000173327; -.
DR   PharmGKB; PA30594; -.
DR   VEuPathDB; HostDB:ENSG00000173327; -.
DR   eggNOG; KOG0192; Eukaryota.
DR   GeneTree; ENSGT00940000161064; -.
DR   HOGENOM; CLU_000288_7_14_1; -.
DR   InParanoid; Q16584; -.
DR   OMA; WKREIQD; -.
DR   OrthoDB; 100698at2759; -.
DR   PhylomeDB; Q16584; -.
DR   TreeFam; TF105118; -.
DR   PathwayCommons; Q16584; -.
DR   Reactome; R-HSA-5673000; RAF activation.
DR   Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF.
DR   Reactome; R-HSA-9013148; CDC42 GTPase cycle.
DR   Reactome; R-HSA-9013408; RHOG GTPase cycle.
DR   Reactome; R-HSA-9013424; RHOV GTPase cycle.
DR   Reactome; R-HSA-9649948; Signaling downstream of RAS mutants.
DR   SABIO-RK; Q16584; -.
DR   SignaLink; Q16584; -.
DR   SIGNOR; Q16584; -.
DR   BioGRID-ORCS; 4296; 63 hits in 1110 CRISPR screens.
DR   ChiTaRS; MAP3K11; human.
DR   GeneWiki; MAP3K11; -.
DR   GenomeRNAi; 4296; -.
DR   Pharos; Q16584; Tchem.
DR   PRO; PR:Q16584; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; Q16584; protein.
DR   Bgee; ENSG00000173327; Expressed in sural nerve and 187 other tissues.
DR   ExpressionAtlas; Q16584; baseline and differential.
DR   Genevisible; Q16584; HS.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005874; C:microtubule; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IPI:UniProtKB.
DR   GO; GO:0004706; F:JUN kinase kinase kinase activity; IMP:UniProtKB.
DR   GO; GO:0004709; F:MAP kinase kinase kinase activity; IMP:UniProtKB.
DR   GO; GO:0031434; F:mitogen-activated protein kinase kinase binding; IEA:Ensembl.
DR   GO; GO:0031435; F:mitogen-activated protein kinase kinase kinase binding; IPI:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0031267; F:small GTPase binding; IEA:Ensembl.
DR   GO; GO:0044843; P:cell cycle G1/S phase transition; IMP:UniProtKB.
DR   GO; GO:0008219; P:cell death; IEA:Ensembl.
DR   GO; GO:0007254; P:JNK cascade; IMP:UniProtKB.
DR   GO; GO:0000165; P:MAPK cascade; IMP:UniProtKB.
DR   GO; GO:0007017; P:microtubule-based process; IMP:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IBA:GO_Central.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; IMP:UniProtKB.
DR   GO; GO:0043507; P:positive regulation of JUN kinase activity; IMP:UniProtKB.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   CDD; cd12059; SH3_MLK1-3; 1.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR035779; MLK1-3_SH3.
DR   InterPro; IPR016231; MLK1-4.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR036028; SH3-like_dom_sf.
DR   InterPro; IPR001452; SH3_domain.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   Pfam; PF14604; SH3_9; 1.
DR   PIRSF; PIRSF000556; MAPKKK9_11; 1.
DR   PRINTS; PR00452; SH3DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00220; S_TKc; 1.
DR   SMART; SM00326; SH3; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cytoplasm; Cytoskeleton;
KW   Kinase; Nucleotide-binding; Phosphoprotein; Reference proteome; Repeat;
KW   Serine/threonine-protein kinase; SH3 domain; Transferase.
FT   CHAIN           1..847
FT                   /note="Mitogen-activated protein kinase kinase kinase 11"
FT                   /id="PRO_0000086260"
FT   DOMAIN          41..105
FT                   /note="SH3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00192"
FT   DOMAIN          117..379
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          11..38
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          403..424
FT                   /note="Leucine-zipper 1"
FT   REGION          438..459
FT                   /note="Leucine-zipper 2"
FT   REGION          537..643
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          655..847
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        577..591
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        674..697
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        746..766
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        785..801
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        241
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000250|UniProtKB:Q02779,
FT                   ECO:0000255|PROSITE-ProRule:PRU00159, ECO:0000255|PROSITE-
FT                   ProRule:PRU10027"
FT   BINDING         123..131
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:Q02779,
FT                   ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         144
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000269|PubMed:11053428, ECO:0000269|PubMed:8195146"
FT   MOD_RES         11
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         35
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80XI6"
FT   MOD_RES         277
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:11053428"
FT   MOD_RES         281
FT                   /note="Phosphoserine; by autocatalysis and MAP4K1"
FT                   /evidence="ECO:0000269|PubMed:11053428"
FT   MOD_RES         394
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         507
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         524
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:11969422,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         548
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:23186163"
FT   MOD_RES         555
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:11969422"
FT   MOD_RES         556
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:11969422"
FT   MOD_RES         654
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:11969422"
FT   MOD_RES         693
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         705
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:11969422,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195"
FT   MOD_RES         708
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         724
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:11969422"
FT   MOD_RES         727
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:11969422"
FT   MOD_RES         740
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:11969422"
FT   MOD_RES         748
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195"
FT   MOD_RES         758
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:11969422,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195"
FT   MOD_RES         770
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:11969422"
FT   MOD_RES         789
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:19690332"
FT   MOD_RES         793
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:11969422,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:19690332"
FT   MOD_RES         815
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   VAR_SEQ         1..257
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_056183"
FT   VARIANT         151
FT                   /note="D -> V (in dbSNP:rs34178129)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040703"
FT   VARIANT         252
FT                   /note="P -> H (in dbSNP:rs17855912)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_030604"
FT   VARIANT         282
FT                   /note="A -> G (in dbSNP:rs34594252)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040704"
FT   MUTAGEN         144
FT                   /note="K->A: Greatly reduced autophosphorylation activity."
FT                   /evidence="ECO:0000269|PubMed:11053428,
FT                   ECO:0000269|PubMed:8195146"
FT   MUTAGEN         144
FT                   /note="K->R: Loss of kinase activity. Prevents activation
FT                   of SAPK and MAPK14."
FT                   /evidence="ECO:0000269|PubMed:11053428,
FT                   ECO:0000269|PubMed:8195146"
FT   MUTAGEN         164
FT                   /note="E->A: Greatly reduced autophosphorylation activity."
FT                   /evidence="ECO:0000269|PubMed:8195146"
FT   MUTAGEN         277
FT                   /note="T->A: Severely reduced autophosphorylation activity.
FT                   Prevents phosphorylation of SAPK and MAPK14."
FT                   /evidence="ECO:0000269|PubMed:11053428"
FT   MUTAGEN         277
FT                   /note="T->E: No effect on SAPK activation."
FT                   /evidence="ECO:0000269|PubMed:11053428"
FT   MUTAGEN         278
FT                   /note="T->A: No effect on autophosphorylation activity or
FT                   activation of SAPK and MAPK14."
FT                   /evidence="ECO:0000269|PubMed:11053428"
FT   MUTAGEN         281
FT                   /note="S->A: Reduced autophosphorylation activity. Reduced
FT                   activation of SAPK and MAPK14."
FT                   /evidence="ECO:0000269|PubMed:11053428"
FT   MUTAGEN         281
FT                   /note="S->E: No effect on SAPK activation."
FT                   /evidence="ECO:0000269|PubMed:11053428"
FT   CONFLICT        247..272
FT                   /note="ILLLQPIESDDMEHKTLKITDFGLAR -> SEFLGAWLGVAWLWYTPAPNLP
FT                   LSLA (in Ref. 4; BAD92892)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        791
FT                   /note="L -> P (in Ref. 4; BAD96501)"
FT                   /evidence="ECO:0000305"
FT   STRAND          45..50
FT                   /evidence="ECO:0007829|PDB:5K26"
FT   STRAND          67..73
FT                   /evidence="ECO:0007829|PDB:5K26"
FT   HELIX           78..80
FT                   /evidence="ECO:0007829|PDB:5K26"
FT   STRAND          83..88
FT                   /evidence="ECO:0007829|PDB:5K26"
FT   STRAND          91..96
FT                   /evidence="ECO:0007829|PDB:5K26"
FT   HELIX           97..99
FT                   /evidence="ECO:0007829|PDB:5K26"
FT   STRAND          100..105
FT                   /evidence="ECO:0007829|PDB:5K26"
SQ   SEQUENCE   847 AA;  92688 MW;  AFB6E930EA281C15 CRC64;
     MEPLKSLFLK SPLGSWNGSG SGGGGGGGGG RPEGSPKAAG YANPVWTALF DYEPSGQDEL
     ALRKGDRVEV LSRDAAISGD EGWWAGQVGG QVGIFPSNYV SRGGGPPPCE VASFQELRLE
     EVIGIGGFGK VYRGSWRGEL VAVKAARQDP DEDISVTAES VRQEARLFAM LAHPNIIALK
     AVCLEEPNLC LVMEYAAGGP LSRALAGRRV PPHVLVNWAV QIARGMHYLH CEALVPVIHR
     DLKSNNILLL QPIESDDMEH KTLKITDFGL AREWHKTTQM SAAGTYAWMA PEVIKASTFS
     KGSDVWSFGV LLWELLTGEV PYRGIDCLAV AYGVAVNKLT LPIPSTCPEP FAQLMADCWA
     QDPHRRPDFA SILQQLEALE AQVLREMPRD SFHSMQEGWK REIQGLFDEL RAKEKELLSR
     EEELTRAARE QRSQAEQLRR REHLLAQWEL EVFERELTLL LQQVDRERPH VRRRRGTFKR
     SKLRARDGGE RISMPLDFKH RITVQASPGL DRRRNVFEVG PGDSPTFPRF RAIQLEPAEP
     GQAWGRQSPR RLEDSSNGER RACWAWGPSS PKPGEAQNGR RRSRMDEATW YLDSDDSSPL
     GSPSTPPALN GNPPRPSLEP EEPKRPVPAE RGSSSGTPKL IQRALLRGTA LLASLGLGRD
     LQPPGGPGRE RGESPTTPPT PTPAPCPTEP PPSPLICFSL KTPDSPPTPA PLLLDLGIPV
     GQRSAKSPRR EEEPRGGTVS PPPGTSRSAP GTPGTPRSPP LGLISRPRPS PLRSRIDPWS
     FVSAGPRPSP LPSPQPAPRR APWTLFPDSD PFWDSPPANP FQGGPQDCRA QTKDMGAQAP
     WVPEAGP
//
